United States Health

Evotec (NASDAQ:EVO) entered a research partnership with Odyssey Therapeutics (NASDAQ:ODTX) to identify small-molecule candidates for autoimmune and inflammatory diseases.

Newmark (NASDAQ:NMRK) acquired L+P Immobilienbewertungs, adding more than 40 German valuation professionals, although the transaction’s financial terms were not disclosed.

Edgewell Personal Care (NYSE:EPC) reported fiscal third-quarter net sales of $570.1 million, up 1.7%, as North American organic sales returned to growth.

Elanco Animal Health (NYSE:ELAN) reported second-quarter revenue of $1.368 billion, up 10%, as Pet Health and Farm Animal sales increased.

CVS Health (NYSE:CVS) reported second-quarter revenues of $106.1 billion, representing a 7.3% increase driven by broad segment gains.

Lilly (NYSE:LLY) reported second-quarter revenue of $23 billion, up 48%, as demand for Mounjaro and Zepbound supported volume growth.

BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.705 billion, up 30%, as BRUKINSA sales expanded globally.

Pfizer (NYSE:PFE) reported second-quarter revenue of $15.03 billion, up 3%, while adjusted diluted earnings reached $0.77 per share.

IDEAYA Biosciences (NASDAQ:IDYA) said OptimUM-02 met its primary endpoint, extending median progression-free survival to 6.9 months from 3.1 months.

Henry Schein (NASDAQ:HSIC) reported second-quarter net sales of $3.458 billion, up 6.7%, with internal sales growth of 4.6%.

IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter revenue of $1.217 billion, up 10%, while diluted EPS increased 18% to $4.27.

Merck (NYSE:MRK) reported second-quarter sales of $16.61 billion, up 5%, as Keytruda and Keytruda QLEX sales reached $8.37 billion.